These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 372653)

  • 1. Characteristics of cytotoxic antibodies against neuraminidase-treated lymphocytes in man.
    Johannsen R; Sedlacek HH; Schmidtberger R; Schick HJ; Seiler FR
    J Natl Cancer Inst; 1979 Apr; 62(4):733-42. PubMed ID: 372653
    [No Abstract]   [Full Text] [Related]  

  • 2. Increase in titer of the naturally occurring human antibody to neuraminidase-treated lymphocytes after influenza.
    Rogentine GN; Doherty CM; Pincus SH
    J Immunol; 1977 Nov; 119(5):1652-4. PubMed ID: 915272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lymphocytes HLA antigens expressivity after neuraminidase treatment (author's transl)].
    de Mouzon A; Ohayon E; Oksman-Domejean F; Ducos J
    Ann Immunol (Paris); 1976; 127(5):687-701. PubMed ID: 984732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro methods for assessment of antibody-mediated tumor immunity.
    Levy NL; Amos DB; Solovieff GV; dos Reis AP
    Natl Cancer Inst Monogr; 1972 Dec; 35():5-11. PubMed ID: 4349154
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection and localization of a lectin on Actinomyces viscosus T14V by monoclonal antibodies.
    Cisar JO; Barsumian EL; Curl SH; Vatter AE; Sandberg AL; Siraganian RP
    J Immunol; 1981 Oct; 127(4):1318-22. PubMed ID: 6115881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a synthetic hapten in the demonstration of the Thomsen-Friedenreich (T) antigen on neuraminidase-treated human red blood cells and lymphocytes.
    Bray J; Lemieux RU; McPherson TA
    J Immunol; 1981 May; 126(5):1966-9. PubMed ID: 7217675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies of immunoglobulin receptors and antibody-dependent cell cytotoxicity (ADCC) in rat lymphoid organs.
    Kedar E; Ortiz de Landazuri M; Fahey JL
    J Immunol; 1974 Jan; 112(1):37-46. PubMed ID: 4130151
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics of a cytotoxic human lymphocyte-dependent antibody.
    Wunderlich J; Rosenberg E; Connolly J; Parks J
    J Natl Cancer Inst; 1975 Mar; 54(3):537-47. PubMed ID: 1168262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes.
    Hale G; Clark M; Waldmann H
    J Immunol; 1985 May; 134(5):3056-61. PubMed ID: 3980990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Course of antibodies in men after vaccination with the inactivated influenca vaccine Alorbat (author's transl)].
    Pressler K; Schenk KD
    Med Klin; 1978 Sep; 73(38):1321-6. PubMed ID: 703655
    [No Abstract]   [Full Text] [Related]  

  • 11. Natural antibodies in human immune surveillance.
    Rosenberg SA; Rogentine GN
    Surg Forum; 1972; 23(0):96-8. PubMed ID: 4671037
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating cytotoxic anti-RCC antibody responses in renal cell carcinoma patients.
    Ishibashi M; Matsuda M; Osafune M; Nakano E; Fujioka H; Takaha M; Sonoda T; Kotake T; Watanabe S
    Hinyokika Kiyo; 1983 Feb; 29(2):121-9. PubMed ID: 6677115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses to inactivated influenza vaccines and partial protective effect of anti-neuraminidase antibody against epidemics of A(H3N2) and A(H1N1) influenza.
    Maeda A; Oishi I; Minekawa Y; Kunita N; Funahashi S; Yagura H
    Biken J; 1979 Sep; 22(3):91-8. PubMed ID: 533537
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-neuraminidase antibody response in serum and nasal secretions following intranasal or subcutaneous inactivated A2-Hong Kong-68 influenza virus vaccine.
    Fedson DS; Fulk RV; Huber MA; Reisberg MA; Kasel JA
    J Immunol; 1971 Sep; 107(3):730-7. PubMed ID: 4999093
    [No Abstract]   [Full Text] [Related]  

  • 15. [Practical interest of a micromethod for neuraminidase treatment of lymphocytes in transplantation immunology (author's transl)].
    de Mouzon A; Ohayon E; Durand D; Ducos J
    Pathol Biol (Paris); 1976 Dec; 24(10):685-9. PubMed ID: 796790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-dependent lymphocyte killer function and age.
    McConnachie PR; Rachelefsky G; Stiehm ER; Terasaki PI
    Pediatrics; 1973 Dec; 52(6):795-800. PubMed ID: 4272165
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lysis of leukemia cells with a monoclonal antibody-cocktail (e.g. VIP-pool) and human complement].
    Reiners B; Thränhardt H; Häfer R; Zintl F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(1):84-96. PubMed ID: 2439421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neuraminidase on serological properties of murine lymphoid cells.
    Schlesinger M; Amos BD
    Transplant Proc; 1971 Mar; 3(1):895-7. PubMed ID: 4106346
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunity status of the Milanese population towards B-Hong Kong-8-73, the new B type strain and study of the immunizing activity of the old composition vaccine].
    Profeta ML; Zanetti AR; Bergamini F
    Boll Ist Sieroter Milan; 1973; 52(5):429-35. PubMed ID: 4788200
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclonal antibodies which react with lymphocyte-lysed target cells and which cross-react with complement-lysed ghosts.
    Ward RH; Lachmann PJ
    Immunology; 1985 Sep; 56(1):179-88. PubMed ID: 4043993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.